251.0K XNAS Volume
XNAS 17 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 103,000 | 103,000 | - | - | Stock Option (Right to Buy) | |
| Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 51,500 | 131,500 (0%) | 0% | 0 | Common Stock | |
| Sandell Jacquelyn Fahey | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 41,500 | 123,143 (0%) | 0% | 0 | Common Stock | |
| Sandell Jacquelyn Fahey | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 83,000 | 83,000 | - | - | Stock Option (Right to Buy) | |
| Toby Ferguson | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 63,000 | 168,000 (0%) | 0% | 0 | Common Stock | |
| Toby Ferguson | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 126,000 | 126,000 | - | - | Stock Option (Right to Buy) | |
| Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 145,000 | 441,816 (1%) | 0% | 0 | Common Stock | |
| Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 290,000 | 290,000 | - | - | Stock Option (Right to Buy) | |
| Alfred W. Sandrock | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.24 per share. | 20 Feb 2025 | 11,702 | 296,816 (0%) | 0% | 4.2 | 49,616 | Common Stock |
| Robin Swartz | COO & CBO | Sale of securities on an exchange or to another person at price $ 4.25 per share. | 20 Feb 2025 | 3,894 | 98,397 (0%) | 0% | 4.3 | 16,550 | Common Stock |
| Robin Swartz | COO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 71,250 | 169,647 (0%) | 0% | 0 | Common Stock | |
| Robin Swartz | COO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 142,500 | 142,500 | - | - | Stock Option (Right to Buy) | |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 4.26 per share. | 20 Feb 2025 | 3,305 | 77,718 (0%) | 0% | 4.3 | 14,079 | Common Stock |
| Todd Carter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 92,000 | 92,000 | - | - | Stock Option (Right to Buy) | |
| Todd Carter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 46,000 | 123,718 (0%) | 0% | 0 | Common Stock | |
| Alfred W. Sandrock | President & CEO | Sale of securities on an exchange or to another person at price $ 4.45 per share. | 11 Feb 2025 | 16,644 | 308,518 (0%) | 0% | 4.5 | 74,066 | Common Stock |
| Robin Swartz | COO & CBO | Sale of securities on an exchange or to another person at price $ 4.45 per share. | 11 Feb 2025 | 6,950 | 102,291 (0%) | 0% | 4.5 | 30,928 | Common Stock |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 4.45 per share. | 11 Feb 2025 | 5,413 | 81,023 (0%) | 0% | 4.5 | 24,088 | Common Stock |
| Sandell Jacquelyn Fahey | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 4.45 per share. | 11 Feb 2025 | 4,358 | 81,643 (0%) | 0% | 4.4 | 19,393 | Common Stock |
| Robin Swartz | COO & CBO | Sale of securities on an exchange or to another person at price $ 5.09 per share. | 14 Jan 2025 | 3,087 | 109,241 (0%) | 0% | 5.1 | 15,713 | Common Stock |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 5.13 per share. | 14 Jan 2025 | 1,191 | 86,436 (0%) | 0% | 5.1 | 6,110 | Common Stock |
| Robin Swartz | COO&CBO | Sale of securities on an exchange or to another person at price $ 5.65 per share. | 23 Dec 2024 | 6,500 | 112,328 (0%) | 0% | 5.7 | 36,725 | Common Stock |
| Sandell Jacquelyn Fahey | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 5.82 per share. | 02 Oct 2024 | 5,999 | 86,001 (0%) | 0% | 5.8 | 34,914 | Common Stock |
| Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 80,000 | 80,000 (0%) | 0% | 0 | Common Stock | |
| Nathan Jorgensen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| James A. Geraghty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| George A. Scangos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Glenn F. Pierce | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Catherine J. Mackey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Steven E. Hyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Grace E. Colon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Nancy Vitale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Jude Onyia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Alfred W. Sandrock | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.86 per share. | 02 Apr 2024 | 12,115 | 322,839 (0%) | 0% | 9.9 | 119,454 | Common Stock |
| Robin Swartz | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 9.88 per share. | 02 Apr 2024 | 1,357 | 117,004 (0%) | 0% | 9.9 | 13,407 | Common Stock |
| Toby Ferguson | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 105,000 | 105,000 (0%) | 0% | 0 | Common Stock | |
| Toby Ferguson | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 210,000 | 210,000 | - | - | Stock Option (Right to Buy) | |
| W. Alfred Sandrock | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.46 per share. | 21 Feb 2024 | 13,033 | 334,954 (0%) | 0% | 7.5 | 97,226 | Common Stock |
| Peter Pfreundschuh P. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.46 per share. | 21 Feb 2024 | 3,764 | 175,669 (0%) | 0% | 7.5 | 28,079 | Common Stock |
| Robin Swartz | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 7.45 per share. | 21 Feb 2024 | 3,966 | 118,361 (0%) | 0% | 7.5 | 29,547 | Common Stock |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.47 per share. | 20 Feb 2024 | 3,365 | 87,627 (0%) | 0% | 7.5 | 25,137 | Common Stock |
| Carter Todd | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.68 per share. | 20 Feb 2024 | 602 | 90,992 (0%) | 0% | 7.7 | 4,623 | Common Stock |
| Fahey Sandell Jacquelyn | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 62,000 | 62,000 | - | - | Stock Option (Right to Buy) | |
| Todd Carter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 77,000 | 77,000 | - | - | Stock Option (Right to Buy) | |
| W. Sandrock Alfred | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 260,000 | 260,000 | - | - | Stock Option (Right to Buy) | |
| Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 130,000 | 347,987 (0%) | 0% | 0 | Common Stock | |
| Carter Todd | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 38,500 | 91,594 (0%) | 0% | 0 | Common Stock | |
| Robin Swartz | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| P. Peter Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Sandell Fahey Jacquelyn | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 31,000 | 92,000 (0%) | 0% | 0 | Common Stock | |
| Swartz Robin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 50,000 | 122,327 (0%) | 0% | 0 | Common Stock | |
| Pfreundschuh P. Peter | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 30,000 | 179,433 (0%) | 0% | 0 | Common Stock | |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.18 per share. | 17 Jan 2024 | 1,266 | 53,094 (0%) | 0% | 7.2 | 9,090 | Common Stock |
| Swartz Robin | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 7.15 per share. | 17 Jan 2024 | 2,543 | 72,327 (0%) | 0% | 7.1 | 18,182 | Common Stock |
| Sandell Jacquelyn Fahey | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 122,000 | 122,000 | - | - | Stock Option (Right to Buy) | |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.80 per share. | 06 Jul 2023 | 5,500 | 59,860 (0%) | 0% | 10.8 | 59,400 | Common Stock |
| Todd Carter | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 5,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.41 per share. | 30 Jun 2023 | 5,000 | 65,360 (0%) | 0% | 11.4 | 57,050 | Common Stock |
| Todd Carter | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.85 per share. | 30 Jun 2023 | 5,000 | 70,360 (0%) | 0% | 2.9 | 14,250 | Common Stock |
| James A. Geraghty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| George A. Scangos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Glenn F. Pierce | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Catherine J. Mackey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Steven E. Hyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Grace E. Colon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Nancy Vitale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Jude Onyia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| George A. Scangos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2023 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Alfred W. Sandrock | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.83 per share. | 03 Apr 2023 | 7,437 | 214,618 (0%) | 0% | 7.8 | 58,232 | Common Stock |
| Robin Swartz | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 7.83 per share. | 03 Apr 2023 | 1,259 | 71,617 (0%) | 0% | 7.8 | 9,858 | Common Stock |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 7.76 per share. | 20 Mar 2023 | 4,410 | 102,200 (0%) | 0% | 7.8 | 34,222 | Common Stock |
| Robin Swartz | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 7.76 per share. | 20 Mar 2023 | 3,654 | 72,876 (0%) | 0% | 7.8 | 28,355 | Common Stock |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.76 per share. | 20 Mar 2023 | 2,193 | 65,360 (0%) | 0% | 7.8 | 17,018 | Common Stock |
| Robin Swartz | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.20 per share. | 15 Mar 2023 | 15,373 | 76,530 (0%) | 0% | 8.2 | 126,059 | Common Stock |
| Jude Onyia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 120,000 | 222,055 (0%) | 0% | 0 | Common Stock | |
| Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| Peter P. Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 76,000 | 76,000 | - | - | Stock Option (Right to Buy) | |
| Peter P. Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 38,000 | 163,000 (0%) | 0% | 0 | Common Stock | |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 7.45 per share. | 17 Feb 2023 | 3,297 | 106,610 (0%) | 0% | 7.5 | 24,563 | Common Stock |
| Robin Swartz | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Robin Swartz | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 40,000 | 91,903 (0%) | 0% | 0 | Common Stock | |
| Todd Carter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 34,000 | 68,291 (0%) | 0% | 0 | Common Stock | |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.45 per share. | 17 Feb 2023 | 738 | 67,553 (0%) | 0% | 7.4 | 5,498 | Common Stock |
| Todd Carter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 68,000 | 68,000 | - | - | Stock Option (Right to Buy) | |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 7.67 per share. | 13 Feb 2023 | 2,868 | 109,907 (0%) | 0% | 7.7 | 21,998 | Common Stock |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.67 per share. | 13 Feb 2023 | 797 | 34,291 (0%) | 0% | 7.7 | 6,113 | Common Stock |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 10.34 per share. | 17 Jan 2023 | 792 | 112,775 (0%) | 0% | 10.3 | 8,189 | Common Stock |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 9.57 per share. | 17 Jan 2023 | 1,396 | 113,567 (0%) | 0% | 9.6 | 13,360 | Common Stock |
| Robin Swartz | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 9.57 per share. | 17 Jan 2023 | 1,396 | 52,695 (0%) | 0% | 9.6 | 13,360 | Common Stock |
| Robin Swartz | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 10.34 per share. | 17 Jan 2023 | 792 | 51,903 (0%) | 0% | 10.3 | 8,189 | Common Stock |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.34 per share. | 17 Jan 2023 | 400 | 35,088 (0%) | 0% | 10.3 | 4,136 | Common Stock |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.57 per share. | 17 Jan 2023 | 706 | 35,488 (0%) | 0% | 9.6 | 6,756 | Common Stock |
| Todd Carter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 5.17 per share. | 06 Jan 2023 | 388 | 36,582 (0%) | 0% | 5.2 | 2,006 | Common Stock |
| Todd Carter | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 6.41 per share. | 06 Jan 2023 | 388 | 36,194 (0%) | 0% | 6.4 | 2,487 | Common Stock |
| Grace E. Colon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Todd Carter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2022 | 165,000 | 165,000 | - | - | Stock Option (Right to Buy) | |
| Catherine J. Mackey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Higgins | Director | Sale of securities on an exchange or to another person at price $ 6.70 per share. | 14 Jul 2022 | 13,891 | 31,314 (0%) | 0% | 6.7 | 93,070 | Common Stock |
| Glenn F. Pierce | Director | Sale of securities on an exchange or to another person at price $ 6.70 per share. | 14 Jul 2022 | 9,512 | 16,788 (0%) | 0% | 6.7 | 63,730 | Common Stock |
| James A. Geraghty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Glenn F. Pierce | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Steven E. Hyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Nancy Vitale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 8.25 per share. | 04 Apr 2022 | 2,786 | 114,963 (0%) | 0% | 8.3 | 22,985 | Common Stock |
| Robin Swartz | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.25 per share. | 04 Apr 2022 | 1,527 | 52,060 (0%) | 0% | 8.3 | 12,598 | Common Stock |
| Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 940,600 | 940,600 | - | - | Stock Option (Right to Buy) | |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 8.29 per share. | 21 Mar 2022 | 4,897 | 117,807 (0%) | 0% | 8.3 | 40,596 | Common Stock |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 8.67 per share. | 21 Mar 2022 | 58 | 117,749 (0%) | 0% | 8.7 | 503 | Common Stock |
| Julie Burek | VP, Finance | Sale of securities on an exchange or to another person at price $ 8.29 per share. | 21 Mar 2022 | 2,618 | 52,489 (0%) | 0% | 8.3 | 21,703 | Common Stock |
| Julie Burek | VP, Finance | Sale of securities on an exchange or to another person at price $ 8.68 per share. | 21 Mar 2022 | 31 | 52,458 (0%) | 0% | 8.7 | 269 | Common Stock |
| Robin Swartz | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.29 per share. | 21 Mar 2022 | 4,362 | 53,638 (0%) | 0% | 8.3 | 36,161 | Common Stock |
| Robin Swartz | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.69 per share. | 21 Mar 2022 | 51 | 53,587 (0%) | 0% | 8.7 | 443 | Common Stock |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 3.55 per share. | 17 Feb 2022 | 4,100 | 122,704 (0%) | 0% | 3.6 | 14,555 | Common Stock |
| Julie Burek | VP, Finance | Sale of securities on an exchange or to another person at price $ 3.55 per share. | 17 Feb 2022 | 789 | 55,107 (0%) | 0% | 3.6 | 2,801 | Common Stock |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 3.36 per share. | 11 Feb 2022 | 3,252 | 126,804 (0%) | 0% | 3.4 | 10,927 | Common Stock |
| Julie Burek | VP, Finance | Sale of securities on an exchange or to another person at price $ 3.36 per share. | 11 Feb 2022 | 361 | 55,896 (0%) | 0% | 3.4 | 1,213 | Common Stock |
| Alfred W. Sandrock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2022 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Robin Swartz | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2022 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Higgins | Director, Interim President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2022 | 161,000 | 161,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Higgins | Director, Interim President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2022 | 45,205 | 45,205 (0%) | 0% | 0 | Common Stock | |
| Glenn F. Pierce | Director, Interim CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2022 | 26,300 | 26,300 (0%) | 0% | 0 | Common Stock | |
| Glenn F. Pierce | Director, Interim CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Robert W. Hesslein | Senior VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2022 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Robert W. Hesslein | Senior VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2022 | 20,000 | 130,056 (0%) | 0% | 0 | Common Stock | |
| Julie Burek | VP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2022 | 10,000 | 56,257 (0%) | 0% | 0 | Common Stock | |
| Julie Burek | VP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Julie Burek | VP, Finance | Sale of securities on an exchange or to another person at price $ 2.83 per share. | 03 Jan 2022 | 3,063 | 46,522 (0%) | 0% | 2.8 | 8,668 | Common Stock |
| Julie Burek | VP, Finance | Sale of securities on an exchange or to another person at price $ 3.06 per share. | 03 Jan 2022 | 265 | 46,257 (0%) | 0% | 3.1 | 811 | Common Stock |
| Julie Burek | VP, Finance | Grant, award, or other acquisition of securities at price $ 2.30 per share. | 03 Jan 2022 | 3,063 | 49,585 (0%) | 0% | 2.3 | 7,045 | Common Stock |
| Julie Burek | VP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Nov 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Julie Burek | VP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Nov 2021 | 13,500 | 46,522 (0%) | 0% | 0 | Common Stock | |
| Glenn Pierce | Director, Interim CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| James A. Geraghty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Mark J. Levin | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Higgins | Director, Interim President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| Steven M. Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Glenn Pierce | Director, Interim CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Steven Hyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Nancy Vitale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Omar Khwaja | See remarks | Sale of securities on an exchange or to another person at price $ 4.03 per share. | 21 May 2021 | 3,516 | 120,509 (0%) | 0% | 4.0 | 14,169 | Common Stock |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 4.95 per share. | 05 Apr 2021 | 3,292 | 110,056 (0%) | 0% | 4.9 | 16,295 | Common Stock |
| Robert W. Hesslein | Senior VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 30,000 | 113,348 (0%) | 0% | 0 | Common Stock | |
| Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 30,000 | 109,894 (0%) | 0% | 0 | Common Stock | |
| G. Andre Turenne | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 80,000 | 322,375 (0%) | 0% | 0 | Common Stock | |
| Omar Khwaja | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 35,000 | 124,025 (0%) | 0% | 0 | Common Stock | |
| Robert W. Hesslein | Senior VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 68,000 | 68,000 | - | - | Stock Option (Right to Buy) | |
| Robert W. Hesslein | Senior VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 34,000 | 83,348 (0%) | 0% | 0 | Common Stock | |
| Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 34,000 | 79,894 (0%) | 0% | 0 | Common Stock | |
| Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 68,000 | 68,000 | - | - | Stock Option (Right to Buy) | |
| G. Andre Turenne | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 94,000 | 242,375 (0%) | 0% | 0 | Common Stock | |
| G. Andre Turenne | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 189,000 | 189,000 | - | - | Stock Option (Right to Buy) | |
| Omar Khwaja | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 36,000 | 89,025 (0%) | 0% | 0 | Common Stock | |
| Omar Khwaja | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 72,000 | 72,000 | - | - | Stock Option (Right to Buy) | |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 7.55 per share. | 11 Feb 2021 | 3,186 | 49,348 (0%) | 0% | 7.5 | 24,054 | Common Stock |
| Allison Dorval | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.55 per share. | 11 Feb 2021 | 3,186 | 45,894 (0%) | 0% | 7.5 | 24,054 | Common Stock |
| G. Andre Turenne | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 7.55 per share. | 11 Feb 2021 | 7,977 | 148,375 (0%) | 0% | 7.5 | 60,226 | Common Stock |
| Omar Khwaja | See remarks | Sale of securities on an exchange or to another person at price $ 7.55 per share. | 11 Feb 2021 | 3,475 | 53,025 (0%) | 0% | 7.5 | 26,236 | Common Stock |
| Allison Dorval | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.62 per share. | 12 Jan 2021 | 2,942 | 49,080 (0%) | 0% | 8.6 | 25,360 | Common Stock |
| G. Andre Turenne | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 8.62 per share. | 12 Jan 2021 | 10,443 | 156,352 (0%) | 0% | 8.6 | 90,019 | Common Stock |
| Nancy Vitale | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| James A. Geraghty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Mark J. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Steven M. Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Glenn Pierce | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Steven Hyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Omar Khwaja | See remarks | Sale of securities on an exchange or to another person at price $ 12.96 per share. | 21 May 2020 | 3,500 | 56,500 (0%) | 0% | 13.0 | 45,360 | Common Stock |
| Robert W. Hesslein | Senior VP & General Counsel | Sale of securities on an exchange or to another person at price $ 8.51 per share. | 03 Apr 2020 | 3,091 | 52,534 (0%) | 0% | 8.5 | 26,304 | Common Stock |
| Robert W. Hesslein | Senior VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2020 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Robert W. Hesslein | Senior VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2020 | 27,500 | 55,625 (0%) | 0% | 0 | Common Stock | |
| Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2020 | 27,500 | 52,022 (0%) | 0% | 0 | Common Stock | |
| Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2020 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| G. Andre Turenne | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2020 | 162,500 | 162,500 | - | - | Stock Option (Right to Buy) | |
| G. Andre Turenne | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2020 | 81,250 | 166,795 (0%) | 0% | 0 | Common Stock | |
| Omar Khwaja | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2020 | 30,000 | 60,000 (0%) | 0% | 0 | Common Stock | |
| Omar Khwaja | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2020 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Allison Dorval | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.36 per share. | 21 Jan 2020 | 3,128 | 24,522 (0%) | 0% | 13.4 | 41,790 | Common Stock |
| Matthew P. Ottmer | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 13.36 per share. | 21 Jan 2020 | 3,724 | 26,276 (0%) | 0% | 13.4 | 49,753 | Common Stock |
| G. Andre Turenne | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 13.36 per share. | 21 Jan 2020 | 10,705 | 85,545 (0%) | 0% | 13.4 | 143,019 | Common Stock |
| James A. Geraghty | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2019 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Mark J. Levin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2019 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Higgins | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2019 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Steven M. Paul | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2019 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Wendy L. Dixon | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2019 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Perry A. Karsen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2019 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Glenn Pierce | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2019 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Steven Hyman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2019 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Omar Khwaja | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2019 | 30,000 | 30,000 (0%) | 0% | 0 | Common Stock | |
| Omar Khwaja | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2019 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Robert W. Hesslein | Senior VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 28,125 | 28,125 (0%) | 0% | 0 | Common Stock | |
| Robert W. Hesslein | Senior VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 168,750 | 168,750 | - | - | Stock Option (Right to Buy) | |
| Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2019 | 25,000 | 26,106 (0%) | 0% | 0 | Common Stock | |
| Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2019 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Dinah Sah | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2019 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Dinah Sah | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2019 | 25,000 | 163,688 (0%) | 0% | 0 | Common Stock | |
| Matthew P. Ottmer | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2019 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Matthew P. Ottmer | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2019 | 30,000 | 30,000 (0%) | 0% | 0 | Common Stock | |
| G. Andre Turenne | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2019 | 96,250 | 96,250 (0%) | 0% | 0 | Common Stock | |
| G. Andre Turenne | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2019 | 192,500 | 192,500 | - | - | Stock Option (Right to Buy) | |
| Allison Dorval | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2018 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Mark J. Levin | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 19 Sep 2018 | 1,500,000 | 6,391,176 (19%) | 4% | 0 | Common Stock | |
| Glenn Pierce | None | Purchase of securities on an exchange or from another person at price $ 18.44 per share. | 12 Sep 2018 | 5,000 | 5,000 (0%) | 0% | 18.4 | 92,200 | Common Stock |
| James A. Geraghty | None | Purchase of securities on an exchange or from another person at price $ 19.39 per share. | 10 Sep 2018 | 3,000 | 76,588 (0%) | 0% | 19.4 | 58,170 | Common Stock |
| James A. Geraghty | None | Purchase of securities on an exchange or from another person at price $ 18.31 per share. | 17 Aug 2018 | 3,000 | 73,588 (0%) | 0% | 18.3 | 54,930 | Common Stock |
| G. Andre Turenne | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2018 | 650,000 | 650,000 | - | - | Stock Option (Right to Buy) | |
| Mark J. Levin | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 20 Jun 2018 | 1,500,000 | 7,891,176 (24%) | 4% | 0 | Common Stock | |
| James A. Geraghty | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Mark J. Levin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Higgins | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Wendy L. Dixon | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Perry A. Karsen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Glenn Pierce | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Steven Hyman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Bernard Ravina | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.38 per share. | 10 Apr 2018 | 2,451 | 0 (0%) | 0% | 18.4 | 45,049 | Common Stock |
| Jane Pritchett Henderson | Sr. V.P. & CFO, Corp. Dev. | Sale of securities on an exchange or to another person at price $ 20.52 per share. | 22 Mar 2018 | 11,200 | 0 (0%) | 0% | 20.5 | 229,824 | Common Stock |
| Jane Pritchett Henderson | Sr. V.P. & CFO, Corp. Dev. | Sale of securities on an exchange or to another person at price $ 21.07 per share. | 22 Mar 2018 | 19,900 | 0 (0%) | 0% | 21.1 | 419,293 | Common Stock |
| Jane Pritchett Henderson | Sr. V.P. & CFO, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.97 per share. | 22 Mar 2018 | 19,900 | 19,900 (0%) | 0% | 12.0 | 238,203 | Common Stock |
| Jane Pritchett Henderson | Sr. V.P. & CFO, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Mar 2018 | 19,900 | 176,784 | - | - | Stock Option (Right to Buy) | |
| Jane Pritchett Henderson | Sr. V.P. & CFO, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Mar 2018 | 11,200 | 165,584 | - | - | Stock Option (Right to Buy) | |
| Jane Pritchett Henderson | Sr. V.P. & CFO, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.97 per share. | 22 Mar 2018 | 11,200 | 11,200 (0%) | 0% | 12.0 | 134,064 | Common Stock |
| Jane Pritchett Henderson | CFO & SVP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.97 per share. | 16 Mar 2018 | 15,416 | 15,416 (0%) | 0% | 12.0 | 184,530 | Common Stock |
| Jane Pritchett Henderson | CFO & SVP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2018 | 15,416 | 198,584 | - | - | Stock Option (Right to Buy) | |
| Jane Pritchett Henderson | CFO & SVP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2018 | 1,900 | 196,684 | - | - | Stock Option (Right to Buy) | |
| Jane Pritchett Henderson | CFO & SVP, Corp. Dev. | Sale of securities on an exchange or to another person at price $ 21.76 per share. | 16 Mar 2018 | 1,900 | 0 (0%) | 0% | 21.8 | 41,344 | Common Stock |
| Jane Pritchett Henderson | CFO & SVP, Corp. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.97 per share. | 16 Mar 2018 | 1,900 | 1,900 (0%) | 0% | 12.0 | 22,743 | Common Stock |
| Jane Pritchett Henderson | CFO & SVP, Corp. Dev. | Sale of securities on an exchange or to another person at price $ 22.15 per share. | 16 Mar 2018 | 15,416 | 0 (0%) | 0% | 22.1 | 341,464 | Common Stock |
| Bernard Ravina | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.16 per share. | 12 Mar 2018 | 2,451 | 2,451 (0%) | 0% | 25.2 | 61,667 | Common Stock |
| Jane Pritchett Henderson | Sr. V.P. & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2018 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Steven M. Paul | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2018 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Dinah Sah | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2018 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Bernard Ravina | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2018 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Matthew P. Ottmer | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2018 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Dinah Sah | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 27 Feb 2018 | 2,184 | 140,872 (0%) | 0% | 7.3 | 15,878 | Common Stock |
| Dinah Sah | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2018 | 4,376 | 28,570 | - | - | Stock Option (Right to Buy) | |
| Dinah Sah | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 27 Feb 2018 | 15,623 | 138,688 (0%) | 0% | 30 | 468,690 | Common Stock |
| Dinah Sah | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.83 per share. | 27 Feb 2018 | 4,063 | 154,311 (0%) | 0% | 11.8 | 48,065 | Common Stock |
| Dinah Sah | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.09 per share. | 27 Feb 2018 | 5,000 | 150,248 (0%) | 0% | 11.1 | 55,450 | Common Stock |
| Dinah Sah | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.33 per share. | 27 Feb 2018 | 4,376 | 145,248 (0%) | 0% | 8.3 | 36,452 | Common Stock |
| Dinah Sah | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2018 | 5,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Dinah Sah | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2018 | 2,184 | 12,957 | - | - | Stock Option (Right to Buy) | |
| Dinah Sah | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2018 | 4,063 | 60,937 | - | - | Stock Option (Right to Buy) | |
| Bernard Ravina | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.24 per share. | 12 Feb 2018 | 2,451 | 4,902 (0%) | 0% | 18.2 | 44,706 | Common Stock |
| Bernard Ravina | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.40 per share. | 10 Jan 2018 | 3,630 | 7,353 (0%) | 0% | 16.4 | 59,532 | Common Stock |
| Bernard Ravina | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.63 per share. | 11 Dec 2017 | 5,490 | 10,983 (0%) | 0% | 13.6 | 74,829 | Common Stock |
| Bernard Ravina | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.26 per share. | 10 Nov 2017 | 5,490 | 16,473 (0%) | 0% | 13.3 | 72,797 | Common Stock |
| Bernard Ravina | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.33 per share. | 10 Oct 2017 | 10,980 | 21,963 (0%) | 0% | 20.3 | 223,223 | Common Stock |
| Matthew P. Ottmer | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2017 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Bernard Ravina | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 05 Sep 2017 | 5,490 | 17,157 (0%) | 0% | 10 | 54,900 | Common Stock |
| Bernard Ravina | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.30 per share. | 20 Jul 2017 | 10,980 | 32,943 (0%) | 0% | 14.3 | 157,014 | Common Stock |
| Bernard Ravina | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 20 Jul 2017 | 5,490 | 49,413 (0%) | 0% | 10 | 54,900 | Common Stock |
| James A. Geraghty | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Mark J. Levin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Higgins | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Wendy L. Dixon | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Perry A. Karsen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Glenn Pierce | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Steven Hyman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Mark J. Levin | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 12 Apr 2017 | 920,000 | 9,391,176 (36%) | 3% | 0 | Common Stock | |
| Steven M. Paul | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2017 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| Jane Pritchett Henderson | Sr. V.P. & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2017 | 214,000 | 214,000 | - | - | Stock Option (Right to Buy) | |
| Wendy L. Dixon | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2017 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Glenn Pierce | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2017 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Robert Tepper | Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 19 Dec 2016 | 750,000 | 10,311,176 | - | - | Common Stock | |
| Mark J. Levin | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 19 Dec 2016 | 750,000 | 10,311,176 | - | - | Common Stock | |
| James A. Geraghty | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2016 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Michael J. Higgins | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2016 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Mark J. Levin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2016 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Perry A. Karsen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2016 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Steven Hyman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2016 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Steven M. Paul | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2016 | 200,000 | 200,000 | - | - | Stock Options (Right to Buy) | |
| J. Jeffrey Goater | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2016 | 40,000 | 40,000 | - | - | Stock Options (Right to Buy) | |
| J. Jeffrey Goater | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2016 | 25,000 | 65,000 | - | - | Stock Options (Right to Buy) | |
| Steven M. Paul | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Jan 2016 | 10,000 | 872,351 | - | - | Common Stock | |
| Robert Tepper | Ten Percent Owner | 16 Nov 2015 | 10,588,235 | 11,061,176 | - | - | Common Stock | ||
| Robert Tepper | Ten Percent Owner | 16 Nov 2015 | 45,000,000 | 0 | - | - | Series A Preferred Stock | ||
| Mark J. Levin | None | 16 Nov 2015 | 10,588,235 | 11,061,176 | - | - | Common Stock | ||
| Mark J. Levin | None | 16 Nov 2015 | 45,000,000 | 0 | - | - | Series A Preferred Stock |